Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

ClinicalTrials.gov ID: NCT06052852

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06052852. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies

Study identification

NCT ID: NCT06052852
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bolt Biotherapeutics, Inc.; Industry
Enrollment: 17 participants

Conditions and interventions

Conditions

Interventions

BDC-3042 Drug
Cemiplimab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 11, 2023 (Actual)
Primary completion: Aug 1, 2025 (Actual)
Completion: Aug 1, 2025 (Actual)
Last update posted: Nov 17, 2025

2023 – 2025

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
Stanford Cancer Center	Palo Alto	California	94304	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
NEXT Oncology	Austin	Texas	78758	—
MD Anderson Cancer Center	Houston	Texas	77030	—
NEXT Oncology	San Antonio	Texas	78229	—
NEXT Virginia	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06052852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 17, 2025 · Synced Nov 14, 2026